<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>EFFERVESCENT POTASSIUM CHLORIDE - potassium chloride, lysine hydrochloride and potassium bicarbonate tablet, effervescent </strong><br>Qualitest Pharmaceuticals<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>Package Insert</h1>
<p class="First"><span class="Bold">DESCRIPTION:</span>  An oral potassium supplement.  each effervescent tablet in solution provides the equivalent of 25 mEq (1865 mg) potassium chloride (supplied by 1.25 g potassium chloride, 0.7  g potassium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> and 1.5 g l-lysine monohydrochloride) with 0.77 g citric acid, FD and C Yellow No. 6 (Sunset Yellow), FD and C Yellow No. 6 Lake as color additives, natural and artificial flavor, and saccharin.<br></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<p class="First"><span class="Bold">CLINICAL PHARMACOLOGY:</span>  Potassium ion is the principal intracellular cation of most body tissues.  Potassium ions participate in many essential physiological processes, such as the maintenance of intracellular ionicity, nerve impulse transmission, enzymatic reactions in intermediary metabolism, cardiac, skeletal and smooth muscle function, and the maintenance of normal renal function.</p>
<p>Potassium depletion may occur whenever the rate of potassium loss through renal excretion and/or loss from the gastrointestinal tract exceeds the rate of potassium intake.  Potassium depletion usually develops slowly as a result of lengthy therapy with oral diuretics, primary or secondary hyperaldosteronism, , <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>, or inadequate replacement of potassium in patients on prolonged parenteral nutrition.  Depletion is additionally associated with severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, accompanied by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.  Potassium depletion due to these causes is usually accompanied by a concomitant loss of chloride and is manifested by <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>.  Potassium depletion may result in <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, loss of appetite, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and chronic <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span> with <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>.  <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Potassium deficiency</span> may be manifested by <span class="product-label-link" type="condition" conceptid="4302536" conceptname="Shallow breathing">shallow breathing</span>, <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">lowered blood pressure</span>, disturbances of cardiac rhythm (primarily ectopic beats), prominent U-waves in the electrocardiogram, or other ECG changes, such as lengthened Q-T interval, depressed S-T segment, and depressed or inverted T-wave.  In advanced cases of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">potassium deficiency</span>, <span class="product-label-link" type="condition" conceptid="4193951" conceptname="Flaccid paralysis">flaccid paralysis</span> and/or impaired ability to concentrate urine may be evident.<br></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<br><span class="Bold">INDICATIONS AND USAGE:</span><br>1. For therapeutic use in patients with <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> with or without <span class="product-label-link" type="condition" conceptid="4030381" conceptname="Metabolic alkalosis">metabolic alkalosis</span>, in <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digitalis intoxication</span> and in patients with hypokalemic familial<br>    periodic <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>.<br>2. For prevention of potassium depletion when the dietary intake of potassium is inadequate in the following conditions:  patients receiving digitalis and<br>    diuretics for <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>; <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> with ascities; states of aldosterone excess with normal renal function; potassium-losing<br>    <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">nephropathy</span>, and certain diarrheal states.<br>3. The use of potassium salts in patients receiving diuretics for uncomplicated <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> is often unnecessary when such patients have a<br>    normal dietary pattern.  Serum potassium should be checked periodically, however, and, if <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> occurs, dietary supplementation with<br>    potassium-containing foods may be adequate to control milder cases.  In more severe cases supplementation with potassium salts may be<br>    indicated.<br>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<p class="First"><span class="Bold">CONTRAINDICATIONS:</span>  Potassium supplements are contraindicated for patients having <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, since a further increase in serum potassium level in these patients can result in <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>.  <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> may complicate any of the following conditions: <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">chronic renal failure</span>; systemic <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, such as <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic acidosis</span>; acute <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>; extensive tissue breakdown, as in severe <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>; <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">adrenal insufficiency</span>.  <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> should not be treated by the simultaneous use of potassium salts and a potassium sparing diuretic, such as spironolactone or triamterene, since the concomitant use of these medications can result in severe hyperkalmia.<br></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<br><span class="Bold">WARNINGS:</span>  The administration of potassium salts can produce <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> in patients with impaired mechanisms for potassium excretion.  These reactions most commonly occur in patients receiving potassium intravenously, but may also occur in patents receiving oral potassium.  Potentially fatal <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> can develop quickly and be asymptomatic.  Patients using potassium salts with chronic <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, or any other condition which impairs the excretion of potassium, require especially careful monitoring of serum potassium concentration and appropriate adjustment of dosage.<br>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<p class="First"><span class="Bold">PRECAUTIONS:</span>  General Precautions - The diagnosis of potassium depletion is ordinarily made by demonstrating <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> in a patient with a clinical history suggesting a cause for potassium depletion.  When interpreting the serum potassium concentration, the physician should be aware that acute <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span> can cause <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> without showing a deficit in total body potassium.  <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">Acute acidosis</span> can increase the serum potassium level to normal even with a reduced total body potassium.  Thus close attention to acid-base balance, serum electrolytes, the clinical status of the patient, and the ECG is required in the treatment of potassium depletion.<br></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7"></a><p></p>
<p class="First"><span class="Bold">Information for Patients</span> - Patients should be instructed to dissolve each tablet completely in the required amount of water to reduce the risk of <span class="product-label-link" type="condition" conceptid="4318531" conceptname="Gastrointestinal irritation">gastrointestinal irritation</span> associated with the oral use of concentrated potassium salt products.  Patients should not open foil pouch until time of use.<br></p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-8"></a><p></p>
<p class="First"><span class="Bold">Laboratory Tests</span> - Serum potassium determinations and ECG should be a part of the frequent clinical evaluation of the patient.<br></p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-9"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions</span> - Severe <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> can be produced by the simultaneous administration of potassium supplements and a potassium-sparing diuretic (see Contraindications).  Potassium supplements should be used carefully by patients who are using salt substitutes, because many of these substitutes contain large amounts of potassium.  This simultaneous use could produce <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>.<br></p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-10"></a><p></p>
<p class="First"><span class="Bold">Usage in Pregnancy</span> - Pregnancy Category C - Animal reproduction studies have not been conducted with this effervescent potassium product.  It is unknown whether this product can cause fetal harm when given to a pregnant woman or if it can affect reproductive capacity.  Pregnant women should be given this product only if it is clearly needed.<br></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-11"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers</span> - Because many drugs are excreted in human milk, there exists the potential for serious adverse reactions in nursing infants from oral potassium supplements.  Therefore, it should be decided whether to discontinue nursing or to discontinue the drug, considering the importance of the drug to the mother.<br></p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-12"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use</span> - Safety and effectiveness in children have not been established.<br></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-13"></a><p></p>
<p class="First"><span class="Bold">ADVERSE REACTIONS:</span> <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> are the most common adverse reactions to oral potassium supplements.  These adverse reactions occur most frequently when the preparation is not taken with food, is not properly diluted, or not completely dissolved.</p>
<p><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> occurs infrequently in patients  with normal renal function who receive oral potassium supplements.  The following are symptoms of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>:  <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span>, unexplained <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> in lips, feet, or hands, difficult breathing or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> or heaviness of legs, and unusual <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>.  (See Contraindications, Warning, and Overdosage).<br></p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-14"></a><p></p>
<p class="First"><span class="Bold">OVERDOSAGE:</span>  The use of oral potassium salts by persons with normal renal functions rarely results in serious <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>.  However, if excretory mechanisms are impaired or if potassium is administered too rapidly intravenously, potentially fatal <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> can result (See Contraindications and Warnings).  The earliest clinical signs of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> may be only increased serum potassium concentrations and characteristic ECG changes, such as <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of S-T segment, prolongation of the QT interval, peaking of T-waves and the loss of P-waves.  The above mentioned changes in the ECG most frequently occur when the serum potassium level gets to 7 to 8 mEq per liter.  At a level of 9 to 10 mEq per liter, other clinical manifestations may occur, such as muscle <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>.</p>
<p>The focus of the treatment of severe <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> should be on the reduction of the serum potassium level by furthering the transfer of potassium from the extracellular to the intracellular space.  The treatment may include the following: a) intravenous administration of 1 liter of a 10 percent glucose solution which contains 30 to 40 units of insulin; b) in the acidolic patient, 150 mEq to 300mEq of sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> administered intravenously.  Other actions should include the discontinuing of potassium sparing diuretics and potassium-containing drugs and often the oral use of a cation exchange resin (such as sodium polystyrene sulfonate) in order to eliminate gastrointestinal potassium.  To make sure that the resin moves repidly through the gastrointestinal tract, a nonabsorbable polyhydric alcohol such as sorbitol should be administered in sufficient amounts to cause a soft to semiliquid bowel movement to occur every few hours.</p>
<p>Hemodialysis can also be used as an effective alternative means to remove excess potassium.<br></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-15"></a><p></p>
<p class="First"><span class="Bold">DOSAGE AND ADMINISTRATION:</span>  Adults - One effervescent tablet (25 mEq potassium and chloride) completely dissolved in three to four ounces or more of <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> water and taken two to four times daily, or as directed by physician.  It is suggested this potassium solution be taken with meals and sipped slowly over a five to ten minute period.  Do not open foil pouch until time of use.<br></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-16"></a><p></p>
<p class="First">Boxes of 30 tablets.<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<p class="First"><img alt="image of carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d5a02700-b888-43b0-85c5-ac8938438c9e&amp;name=qualitest%20kcl%20effer%20tabs%2030%20ct%20carton.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EFFERVESCENT POTASSIUM CHLORIDE 		
					</strong><br><span class="contentTableReg">potassium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> and potassium chloride effervescent tablets for oral solution tablet, effervescent</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0603-3508</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>POTASSIUM CHLORIDE</strong> (POTASSIUM CATION and CHLORIDE ION) </td>
<td class="formItem">POTASSIUM CHLORIDE</td>
<td class="formItem">1.25 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>LYSINE HYDROCHLORIDE</strong> (LYSINE) </td>
<td class="formItem">LYSINE HYDROCHLORIDE</td>
<td class="formItem">1.5 g</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>POTASSIUM <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span></strong> (POTASSIUM CATION and <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span> ION) </td>
<td class="formItem">POTASSIUM <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span></td>
<td class="formItem">0.7 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem">0.77 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem">0.45 g</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem">0.077 g</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td>
<td class="formItem">0.041 g</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SACCHARIN SODIUM ANHYDROUS</strong></td>
<td class="formItem">0.04 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">red</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">25mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">FRUIT PUNCH (Fruit Punch Flavor # 464211) </td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">K</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0603-3508-16</td>
<td class="formItem">30  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">unapproved drug other</td>
<td class="formItem"></td>
<td class="formItem">01/06/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Qualitest Pharmaceuticals
							(011103059)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Tower Laboratories Ltd (001587203)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Tower Laboratories Ltd.</td>
<td class="formItem"></td>
<td class="formItem">001587203</td>
<td class="formItem">manufacture</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>fc94a381-48f4-471f-be58-94e7924fd289</div>
<div>Set id: d5a02700-b888-43b0-85c5-ac8938438c9e</div>
<div>Version: 3</div>
<div>Effective Time: 20120424</div>
</div>
</div> <div class="DistributorName">Qualitest Pharmaceuticals</div></p>
</body></html>
